VIRMA and diffuse large B-cell lymphoma: Additionally, highly expressed KIAA1429 showed worse clinical outcomes in patients with DLBCL with DHL, who exhibited a limited response to standard R-CHOP chemoimmunotherapy and tended to present poor prognosis [23], suggesting that KIAA1429 may be a predictor to guide the prognosis of DLBCL.